前列腺癌早期诊断相关性指标的研究进展

洋 金(承德医学院附属医院，中国)
志勇 王(承德医学院附属医院，中国)

摘要

中国是人口大国，在人类寿命延长，生活方式日益西化后，前列腺癌发生率也显著升高。早期前列腺癌适合进行外科根治性手术，可获得较好效果。但多数前列腺癌患者确诊时已经处于进展期或晚期，这一类前列腺癌无有效治疗手段。肿瘤标记物和影像学检查是现今推崇的诊断方式，可减少不必要的穿刺活检，且部分肿瘤标记物具有极高的敏感性与特异性，不仅可辅助临床诊断早期前列腺癌，还可评估前列腺癌的病情严重程度，预测患者的预后情况。论文简单介绍新型前列腺癌生物学和影像学检查，希望能为相关研究人员提供一定参考和借鉴。

关键词

前列腺癌；早期诊断；新型肿瘤标志物；多参数磁共振成像

参考

RAWLA P. Epidemiology of Prostate Cancer[J]. World J Oncol, 2019,10(2):63-89.

Clemmons N S, Wallace G S, Patel M, et al. Incidence of Measles in the United States, 2001-2015[J]. Jama, 2017, 318(13):1279-1281.

闫厚煜,邢金春,张开颜,等.前列腺癌的早期诊断研究进展[J].临床泌尿外科杂志,2020,35(3):242-246.

Lojanapiwat B, Anutrakulchai W, Chongruksut W, et al. Correlation and diagnostic performance of the prostate-specific antigen level with the diagnosis, aggressiveness, and bone metastasis of prostate cancer in clinical practice[J]. Prostate Int, 2014,2(3):133-139.

Sriplakich S, Lojanapiwat B, Chongruksut W, et al. Prospective performance of the Prostate Health Index in prostate cancer detection in the first prostate biopsy of men with a total prostatic specific antigen of 4-10 ng/mL and negative digital rectal examination[J]. Prostate Int, 2018,6(4):136-139.

Simardi L H, Tobias-Machado M, Kappaz G T, et al. Influence of asymptomatic histologic prostatitis on serum prostate-specific antigen: a prospective study[J]. Urology, 2004,64(6):1098-1101.

Nan L B, Yin X T, Gao J P. Significant Diagnostic Value of Free-Serum PSA (FPSA)/Prostate-Specific Antigen Density (PSAD) and (F/T)/PSAD for Prostate Cancer of the Chinese Population in a Single Institution[J]. Med Sci Monit, 2019,25:8345-8351.

付贤,何华东,王于勇,等.血PSA、MRI和超声造影联合应用在前列腺癌中的诊断价值[J].实用肿瘤杂志,2018,33(6):529-532.

Tosoian J J, Druskin S C, Andreas D, et al. Prostate Health Index density improves detection of clinically significant prostate cancer[J]. BJU Int, 2017,120(6):793-798.

De La Calle C, Patil D, Wei J T, et al. Multicenter Evaluation of the Prostate Health Index to Detect Aggressive Prostate Cancer in Biopsy Naïve Men[J]. J Urol, 2015, 194(1):65-72.

Stephan C, Jung K, Lein M, et al. PHI density prospectively improves prostate cancer detection[J]. World J Urol, 2021,39(9):3273-3279.

Bařinka C, Rojas C, Slusher B, et al. Glutamate carboxypeptidase II in diagnosis and treatment of neurologic disorders and prostate cancer[J]. Curr Med Chem, 2012,19(6):856-870.

王子龙,韩承林,王慕文.前列腺特异性膜抗原在泌尿系统肿瘤中的诊疗进展[J].肿瘤综合治疗电子杂志,2020,6(4):63-68.

陈志强,张志根.PSAM和PSAMR与Gleason评分及临床分期的相关性研究[J].临床泌尿外科杂志,2017,32(3):229-231.

Chun F K, De La Taille A, Van Poppel H, et al. Prostate cancer gene 3 (PCA3): development and internal validation of a novel biopsy nomogram[J]. Eur Urol, 2009,56(4):659-667.

De La Taille A, Irani J, Graefen M, et al. Clinical evaluation of the PCA3 assay in guiding initial biopsy decisions[J]. J Urol, 2011,185(6):2119-2125.

张可,蒋伟,黎卓君,等.尿液前列腺癌基因(PCA3)联合多参数磁共振对前列腺癌的诊断价值[J].中华腔镜泌尿外科杂志(电子版),2021,15(6):463-466.

Fiorella D, Marenco J L, Mascarós J M, et al. Role of PCA3 and SelectMDx in the optimization of active surveillance in prostate cancer[J]. Actas Urol Esp (Engl Ed), 2021,45(6):439-446.

Wang F B, Chen R, Ren S C, et al. Prostate cancer antigen 3 moderately improves diagnostic accuracy in Chinese patients undergoing first prostate biopsy[J]. Asian J Androl, 2017,19(2):238-243.

Francavilla A, Turoczi S, Tarallo S, et al. Exosomal microRNAs and other non-coding RNAs as colorectal cancer biomarkers: a review[J]. Mutagenesis, 2020,35(3):243-260.

Mckiernan J, Donovan M J, Margolis E, et al. A Prospective Adaptive Utility Trial to Validate Performance of a Novel Urine Exosome Gene Expression Assay to Predict High-grade Prostate Cancer in Patients with Prostate-specific Antigen 2-10ng/ml at Initial Biopsy[J]. Eur Urol, 2018,74(6):731-738.

Kretschmer A, Tilki D. Biomarkers in prostate cancer - Current clinical utility and future perspectives[J]. Crit Rev Oncol Hematol, 2017,120:180-193.

Lendínez-Cano G, Alonso-Flores J, Beltrán-Aguilar V, et al. Comparison of pathological data between prostate biopsy and radical prostatectomy specimen in patients with low to very low risk prostate cancer[J]. Actas Urol Esp, 2015,39(8):482-487.

Sathianathen N J, Kuntz K M, Alarid-Escudero F, et al. Incorporating Biomarkers into the Primary Prostate Biopsy Setting: A Cost-Effectiveness Analysis[J]. J Urol, 2018,200(6):1215-1220.

安宏斌,聂伟,谢元忠.前列腺中央腺体癌、增生结节3.0T磁共振波谱成像的初步研究[J].中华临床医师杂志(电子版),2016,10(10):1422-1426.

DOI: http://dx.doi.org/10.12345/yzlcyxzz.v7i8.20484